Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX 5 35 SULFITE FREE IN DEXTROSE 35 IN PLASTIC CONTAINER versus TRAVASOL 2 75 IN DEXTROSE 15 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX 5 35 SULFITE FREE IN DEXTROSE 35 IN PLASTIC CONTAINER versus TRAVASOL 2 75 IN DEXTROSE 15 IN PLASTIC CONTAINER.
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER vs TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids and dextrose for protein synthesis and energy metabolism in parenteral nutrition. Dextrose supplies glucose for cellular energy, while amino acids serve as substrates for protein synthesis.
Travasol 2.75% in Dextrose 15% is a parenteral nutrition solution. Travassol provides amino acids for protein synthesis, while dextrose provides caloric energy. The mechanism involves intravenous administration to bypass gastrointestinal absorption, directly delivering substrates for metabolism and tissue repair.
Intravenous administration of 5% amino acids (Clinimix 5/35 refers to 5% amino acids, not 35%; 35% dextrose is not a standard concentration in Clinimix products; assuming a standard Clinimix product: Clinimix 5/35 is not a known concentration; typical Clinimix is 5% or 8% amino acids with varying dextrose concentrations; for this response, considering Clinimix 5/15 or similar; if interpreting as dextrose 35%, that is not possible; assuming correct product is Clinimix 5% amino acids with dextrose, typical adult dose is based on protein requirements: 1-2 g amino acids/kg/day, corresponding to 20-40 mL/kg/day of a 5% amino acid solution, administered as a continuous IV infusion. Maximum infusion rate is generally 4 mg/kg/min for amino acids.
Intravenous infusion: 1000-2000 mL/day (providing 27.5 g amino acids and 150 g dextrose) at a rate not exceeding 4 mL/kg/hour.
None Documented
None Documented
Amino acids: 0.5-1 h (rapid distribution and metabolism); glucose: ~1.5-2 h (insulin-dependent). Clinical context: continuous infusion maintains steady state.
Not applicable as a direct drug; components have variable half-lives: amino acids are rapidly cleared (minutes to hours), dextrose is regulated by insulin (glucose half-life ~1-2 hours in euglycemia).
Renal: 90-100% as free amino acids and glucose metabolites; <5% biliary/fecal.
Travasol 2.75% in dextrose 15% is a parenteral nutrition solution. The amino acids are metabolized and their nitrogen is primarily excreted as urea in urine (renal >90%), with minimal biliary or fecal elimination. Dextrose is metabolized to CO2 and water, exhaled via lungs and excreted renally.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution